

Wednesday, 20 July 2005


FOR IMMEDIATE RELEASE

OBJ accelerates skin cancer drug absorption by 900%

OBJ Limited (OBJ) is pleased to announce that the company's propriety 'smart' drug patch technology had succeeded in increasing the rate of transdermal diffusion of the anti-cancer drug 5-aminolevulinic acid or 5-ALA by almost 900%.

5-ALA is a topical photodynamic drug that is used in the treatment of skin cancers. 5-ALA currently requires up to 3 hours to penetrate, prior to activation by a surgeon using red light. The ability of the OBJ technology to reduce the pre-treatment waiting times to more convenient and practical levels provides cost benefits for both doctors and patients as well as greater market opportunities for pharmaceutical manufacturers of ALA and ALA derivatives.

The results were achieved by the Western Australian Biomedical Research Institute at its drug development facilities at Curtin University.



The study employed donated human female abdominal skin and achieved the greatest improvement over passive diffusion during the important first 30 minutes. These studies require replication in human trials before the exact time savings provided by the OBJ technology can be calculated.

- Ends -

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: jedwards@obi.com.au


OBJ
LIMITED

RESEARCH AND DEVELOPMENT

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride. More recently, it had demonstrated precise control over drug delivery rates and recent finding added an additional time-based control mechanism previously not seen in the drug delivery sector.



OBJ maintains a continuous drug patch and drug delivery program that includes a number of commercially significant anti-inflammatory, anti-pain, anti-oxidant and anti-cancer drugs, as well as a number of cosmetic compounds.

Illustrated above is the OBJ 'smart' coin-sized drug patch system currently under development to improve the drug delivery and efficacy of a range of existing commercial drugs.

Sustainable Benefits

Through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules provides economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Cost reductions are achieved through self administration, reduced administration costs and regulatory costs with a corresponding increase in safety and patient compliance.

Side effects may be reduced in many cases by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems can be eliminated while the reduction in the level of skill required for application can significantly reduce total cost of administration.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University.

The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 9 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au